WASHINGTON, D.C. (April 5, 2006) – Peter F. Young, President and CEO of AlphaVax, Inc., will testify Thursday before the House Energy and Commerce Subcommittee on Health on behalf of the Biotechnology Industry Organization (BIO). The subcommittee hearing is entitled, “Project BioShield Reauthorization Issues.”
AlphaVax is a pre-revenue biotechnology company based in Research Park Triangle, North Carolina that is working to develop and commercialize a vaccine technology with broad potential in infectious disease and cancer, including specific NIH-funded programs for pandemic influenza and biodefense applications. Mr. Young’s testimony will highlight reforms needed to better engage biotechnology companies in biodefense and pandemic countermeasure development, such as the need for clear and predictable identification of countermeasure needs; strong leadership and effective coordination; and sufficient funding through the full development and acquisition processes.
When: Thursday, April 6, 2006 at 1 p.m.
Where: 2123 Rayburn House Office Building
The hearing is scheduled to be webcast. For more information, including a complete witness list and the link to view the hearing by webcast, please visit http://energycommerce.house.gov/108/Hearings/04062006hearing1833/hearing.htm .
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.